Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations
PLOS Pathogens · 08.04.2025 · 21 (4) · e1012971
DOI: 10.1371/journal.ppat.1012971 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PLOS Pathogens, online erschienen am 08.04.2025. Verfasst von Julie Le Bris und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, CNRS UMR3525, Microbial Evolutionary Genomics, Paris, France. Hauptthemen laut MEDLINE: Phage Therapy, Klebsiella pneumoniae, Klebsiella Infections, Bacteriophages. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Sorbonne Université, École Doctorale Complexité du Vivant, Department of Medicine at the University of Pittsburgh School of Medicine.
Abstract (Originalsprache)
Klebsiella pneumoniae (KP) is a Gram-negative bacterium that commonly resides in the human gastrointestinal tract and can also act as an opportunistic pathogen and cause extra-intestinal infections. KP poses a global health threat because it causes both hospital- and community-acquired infections in immune-competent and immunocompromised hosts. These infections can be multidrug-resistant and/or hypervirulent, making KP infections difficult to treat and deadly. In the absence of effective treatments for recalcitrant KP infections, bacteriophage (phage) therapy is gaining attention as a promising alternative. In this review, we evaluate KP epidemiology and epitope diversity, discuss interactions between KP-targeting phages and their bacterial hosts from an eco-evolutionary perspective, and summarize recent efforts in phage therapy for treating KP infections. We also discuss novel approaches, including genetic engineering and machine learning, as initial steps toward developing KP-targeting phage therapy as a precision medicine approach for an emerging and dangerous pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institut Pasteur, Université Paris Cité, CNRS UMR3525, Microbial Evolutionary Genomics, Paris, France.
- Sorbonne Université, Collège Doctoral, Ecole Doctorale Complexité du Vivant, Paris, France.
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
- Laboratoire de Microbiologie et Génétique Moléculaires (LMGM), CNRS UMR5100, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.
- Center for Evolutionary Biology and Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
ORCID-Profile: Daria Van Tyne
Förderung
- NIAID NIH HHS
- Sorbonne Université, École Doctorale Complexité du Vivant
- Department of Medicine at the University of Pittsburgh School of Medicine
- ANR (Agence National de Recherche)
- NIAID
- Department of Medicine, University of Pittsburgh
Zitieren
APA
Le Bris, J., Chen, N., Supandy, A., Rendueles, O., & Van Tyne, D. (2025). Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations. PLOS Pathogens, 21(4), e1012971. https://doi.org/10.1371/journal.ppat.1012971
Vancouver
Le Bris J, Chen N, Supandy A, Rendueles O, Van Tyne D. Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations. PLOS Pathogens. 2025;21(4):e1012971. doi:10.1371/journal.ppat.1012971
BibTeX
@article{LeBris2025,
author = {Le Bris, Julie and Chen, Nathalie and Supandy, Adeline and Rendueles, Olaya and Van Tyne, Daria},
title = {Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {4},
pages = {e1012971},
doi = {10.1371/journal.ppat.1012971}
}
EUVIMED